INTRODUCTION
The effectiveness of inhaled nitrogen oxide (iNO) in improving oxygenation and reducing the need for extracorporeal membrane oxygenation (ECMO) in patients with severe persistent pulmonary hpyertension of the newborn (PPHN) is well established. [1] [2] [3] [4] [5] [6] Most studies to date have enrolled patients with severe PPHN defined as an alveolar-arterial oxygen gradient (AaDO 2 ) >600 Torr or an oxygenation index (OI) >25. Patients with severe PPHN are critically ill and on maximal medical support, which in itself may have detrimental effects. 7 It is possible that earlier initiation of iNO therapy may halt the progression to severe PPHN and thereby have a positive influence on outcome variables. Improved oxygenation may allow a faster weaning of respiratory support, and thereby reduce ventilator-induced lung injury and oxygen toxicity. On the other hand, it is possible that patients with early or moderate PPHN may only have a moderate degree of pulmonary vasoconstriction, and improvement in oxygenation with iNO might be less than that seen with severe PPHN. We therefore conducted a randomized, controlled multicenter trial to assess whether iNO therapy in patients with moderate PPHN would improve arterial p a O 2 , prevent progression to severe PPHN, and improve clinical outcomes.
METHODS
The study was approved by the institutional review board of each participating center and by the Food and Drug Administration (IND # 44,213).
Patients
Patients were recruited into the study from the neonatal intensive care units of 12 participating centers. The only exclusion criterion was the presence of a lethal malformation. Patients with birth weight >2.0 kg, being mechanically ventilated with an FiO 2 of 1.0, and echocardiographic evidence of pulmonary hypertension were eligible for the study. Echocardiographic diagnosis of pulmonary hypertension was based upon the presence of a bidirectional or right-to-left ductal shunt, or a bidirectional or right-to-left atrial shunt with pulmonary artery pressure with Z50% of systolic pressure estimated from tricuspid regurgitant jet or posterior systolic bowing of the intraventricular septum. All patients were initially stabilized with appropriate medical management, including sedation, volume resuscitation, inotropes, alkalinization, and paralysis if needed. By protocol, at least one treatment with surfactant (Survanta, Ross Laboratories, Columbus, OH) prior to study entry was required. If after this period of stabilization the AaDO 2 remained between 500 and 599 Torr on two qualifying blood gases obtained at least 1 h apart, then the patient was eligible for the study. Informed consent was obtained from the parents/ guardians of infants who met entry criteria. Randomization was performed immediately following the second qualifying blood gas after obtaining informed consent. Randomization order was determined a priori, in blocks of 10, by coin toss with folded group assignment cards placed in sequentially numbered opaque envelopes for each center.
Subsequent to randomization, medical management for both groups was at the discretion of the attending neonatologist. Additional treatment with alkalinizing agents, paralysis, sedation, inotropes, or surfactant was permitted. Arterial blood gas analysis was performed at least every 3 hours in the first 12 hours for both groups.
Study Design
Patients assigned to the iNO group received iNO gas at concentrations of 10-80 ppm. Non-response was defined as a r20% initial improvement in AaDO 2 (AaDO 2 ¼ FiO 2 (barometric pressureÀ47)Àp a CO 2 Àp a O 2 ), or oxygenation index (OI ¼ 100 Â FiO 2 Â mean airway pressure/p a O 2 ), and in these patients iNO was discontinued over several minutes. In responders, iNO concentration was titrated to achieve maximal improvement in arterial p a O 2 . During the titration phase arterial blood gases were measured every 30 minutes. Inhaled Nitric Oxide was started at a concentration of 10 ppm followed by stepwise increases of 10-20 ppm every 30 minutes until no further increases in arterial pO 2 occurred or until a maximum iNO concentration of 80 ppm was reached. From this point on, all ventilator parameters, except iNO, were weaned as tolerated. The reason for this strategy was to allow rapid weaning while maximizing arterial pO 2 . Weaning of iNO concentration was only allowed when minimal ventilator settings and an FiO 2 of 0.3-0.5 had been achieved or if methemoglobin levels exceeded 5%. Guidelines for weaning from mechanical ventilation for both groups were to keep the p a CO 2 between 40 and 50 Torr and p a O 2 Z50 Torr. There was no restriction on the ventilation mode that could be used in the study, but switching ventilation modes was not permitted during the titration phase. In study patients, persistent AaDO 2 Z600 Torr of more than 2 hours was considered to be a failure of assigned therapy, and patients meeting this exit criterion were eligible for any other therapies, including iNO, ECMO and prostacyclin, at the discretion of the attending neonatologist. Secondary outcome data on these patients were included in the analysis, but oxygenation data after exiting the study were not analyzed. Control patients with persistent AaDO 2 Z600 Torr were eligible for a rescue protocol with iNO (data not shown, manuscript in preparation).
Nitric Oxide Delivery System
Nitric oxide gas from a source tank at approximately 800 ppm (Scott Medical Products, Plumsteadville, PA; Liquid Carbonic, St. Louis, MO; or Ohmeda, Cherry Hill, NJ) was introduced into the inspiratory limb of the ventilator circuit. Nitric oxide and nitrogen dioxide were sampled continuously from the inspiratory limb close to the patient ''Y'' of the circuit, and their concentrations were measured electrochemically using a Pulmonox II monitor (Pulmonox Research and Development Corp., Tolfield, Alberta, Canada) or an INOVent (Ohmeda Inc., Madison, WI). Expiratory gases were scavenged into the hospital wall vacuum. Nitric oxide concentrations between 0 and 80 ppm were achieved by regulating the flow of gas for the nitric oxide source tank or by dialing in the desired concentration on the INOVent.
Sample Size and Data Analysis
The study was designed to test the null hypothesis that, in patients with moderate pulmonary hypertension, there would be no difference between the iNO and control groups in progression to severe pulmonary hypertension. Failure of assigned therapy, namely iNO or standard therapy (control group), for this study was defined as an AaDO 2 persistently greater than 600 Torr. We estimated that a 20% difference in this primary outcome variable would be clinically significant. Power analysis calculations showed that to demonstrate a 20% difference with alpha ¼ 0.05 and beta ¼ 0.67 would require 100 patients in each group. The study was stopped after a total of 85 patients had been enrolled because it became difficult to enroll patients once iNO was approved by the FDA. Secondary outcome variables included death, ECMO rate, length of hospitalization, amount and duration of mechanical ventilation, number of days of oxygen used, and need for supplemental oxygen at 28 days of life. The amount of mechanical ventilatory support was calculated as a product of mean airway 
RESULTS
A total of 87 patients were enrolled in the study, out of whom two were excluded. No data were available for the first excluded patient because the consent form was missing. The second exclusion was a patient who was randomized to the iNO group, but was transferred shortly after enrollment to another center for possible ECMO. The only information we have from this center is that the baby responded to nitric oxide, did not require ECMO, and was eventually discharged home.
The results for the remaining 85 patients, 43 in the iNO group and 42 in the control group, are presented. There were no differences between the groups in demographic characteristics, treatment modalities, or age at study entry ( Table 1 ). The ventilation status at the time of enrollment was also similar between the two groups. Primary diagnoses at study entry were similar in the groups (Table 2 ). There were five patients with congenital anomalies, two in each group with congenital diaphragmatic hernias and one patient with gastroschisis and sepsis in the iNO group. The latter patient and one patient with diaphragmatic hernia in the iNO group improved with nitric oxide treatment, but the remaining three all required ECMO. There were no deaths in this group. To allow our study results to be compared to earlier studies, data of the five patients with congenital anomalies have been excluded from further analysis. Statistical significance of outcomes in primary or secondary variables does not change if the data of patients with congenital anomalies are included in the analysis.
The primary outcome variable was failure of assigned therapy and progression to severe pulmonary hypertension, defined as a persistent AaDO 2 Z600 Torr. A total of 23 of 40 control patients (57.5%) failed standard therapy compared to only six of 40 patients treated with iNO (15.0%), a four-fold greater failure rate ( p<0.0005). As can be seen from the Kaplan-Meier plot, all the treatment failures in the control group occurred in the first 36 hours (Figure 1 ). Maximal response in arterial p a O 2 occurred at a mean iNO concentration of 33 ppm (median 30, range 10-70 ppm). In 12 patients maximal change in arterial pO 2 occurred at an iNO concentration of 10 ppm. There was only one patient in whom maximal response in arterial p a O 2 was seen at an iNO concentration of 70 ppm. In most patients maximal response in arterial p a O 2 was reached within 3 hours after study entry. The mean p a O 2 in control patients increased from a baseline value of 112±48 to 133±100 ( p ¼ 0.132) compared to an increase from 101±29 to 208±118 ( p<0.0005), respectively, for iNO-treated infants 3 hours after study entry. The improvement in arterial p a O 2 was sustained with consistently lower AaDO 2 levels in iNO-treated infants compared to control patients (Figure 2) . The mean duration of iNO therapy was 96 hours. Methemoglobinemia defined as methemoglobin level >5% did not occur in any patient. The mean methemoglobin for the iNO group was 1.45% (SD±0.95).
Treatment with iNO was associated with a significant decrease in ventilation support compared to control therapy (Figure 3) . A reduced need for ventilation was most significant for the first 36 hours after starting therapy, but a trend towards lower ventilation support for the iNO group persisted up to 120 hours of treatment. Severe pulmonary hypertension defined as an AaDO 2 >600 mmHg was a failure and exit criterion and these patients (especially control infants) were then eligible for rescue with iNO or another therapy at the discretion of the attending neonatologist. Oxygenation data subsequent to exiting the study have not been included in the data presented. There was no difference in secondary outcome variables. There was one death in each group. One patient in the iNO group with septicemia died while on ECMO, while the one in the control group died following a cardiac arrest 3 days after extubation. Autopsy in the latter patient showed interstitial emphysema but was inconclusive as to the cause of death. Four patients in the iNO group (10%) and three in the control group (8%) required ECMO. The duration of mechanical ventilation (8.7±4 vs 10.0±6), supplemental oxygen (14±8 vs 18±17) or hospitalization (21±14 vs 23±11) days were not different for the iNO group compared to the control group. Four patients in the iNO group (10%) and six (15%) in the control group required supplemental oxygen at 28 days of life.
DISCUSSION
We have shown in this randomized controlled study that iNO in patients with moderate pulmonary hypertension improves arterial p a O 2 , reduces the amount of ventilatory support needed, and prevents progression to severe PPHN. Our protocol in this study was to titrate iNO concentration to achieve maximum improvement in arterial p a O 2 and to maintain this level of iNO while trying to wean ventilatory support, including FiO 2 concentration, as much as possible to minimize potential ventilator-induced lung injury and oxygen toxicity. Using this strategy only 15% of iNO-treated patients developed severe pulmonary hypertension compared to 58% of controls (Figure 1 ). Twice as many iNO-treated infants had a sustained improvement in arterial p a O 2 compared to controls. Oxygenation status in the iNO-treated group was significantly better than control patients for the first 36 hours. It should be noted that the plots in Figure 2 represent data for patients still in the study, at each of the time points. Since more than half the control group patients developed severe PPHN and exited the study, the AaDO 2 plot for the control group, especially after 36 hours, is more representative of the relatively less sick patients. It is likely that the difference between the two groups in oxygenation and ventilation support would have been more significant and prolonged if the failure patients did not have the option of rescue iNO therapy, but this was ethically unacceptable. Patients in the iNO group consistently required less ventilation support than control subjects (Figure 3) .
There are only two previous studies of iNO use in moderate or early PPHN, 8, 9 and these differ from ours in several aspects. The first report by Davidson et al, 8 was a randomized, double masked dose-response study in which the primary outcome variables were major sequelae including death, ECMO, neurologic sequelae and chronic lung disease. In this study patients were assigned to 0, 5, 20 or 80 ppm iNO treatment groups with conventional ventilation. Improved oxygenation was seen in the iNO-treated groups compared to the control group, but a dose-response benefit was not demonstrated. Similar to our findings, there were no differences in outcome variables between controls and iNO groups in that study. High-frequency oxillatory ventilation (HFOV) by itself 10 and in addition to iNO 2 has been shown to reduce the need for ECMO in patients with severe PPHN. The second published study with moderate PPHN is by the Franco-Belgium Collaborative NO trial group 9 and includes preterm and near-term infants. This study is difficult to compare because some results for preterm and near-term infants are combined, there are significant exclusions from the iNO groups, and the type of statistical tests used is not mentioned. This study did report a lower OI at 2 hours and a shorter duration of mechanical ventilation (6 versus 7 days) in iNO-treated infants compared to control patients.
Outcome variables, including ECMO and oxygen requirement at 28 days, were no different for the two groups in the present study. This perhaps is related to the study design since control infants who worsened to the stage of severe PPHN were rescued with iNO. Overall, seven (8.8%) patients required ECMO: four from the iNO group and three control patients who failed nitric oxide rescue treatment. The study was stopped prematurely because of problems with enrollment, and we do not have enough power to draw any conclusions about secondary outcome variables. Clark et al., 4 Gupta et al. 11 and the NINOS 3 trial did demonstrate a significant reduction in the need for ECMO in patients with severe PPHN treated with iNO. The Clark study, which involved 248 patients, also showed a lower incidence of chronic lung disease. It is possible that this effect may occur in babies with moderate PPHN as well, because a trend toward a lower incidence of chronic lung disease was seen in the Franco-Belgium study 9 and in our study, but clearly a much larger study is needed to prove this. Other variables such as duration of mechanical ventilation, oxygen use and length of stay have not been shown to be improved with iNO use and may be dependent upon resolution of the underlying pathology, such as meconium aspiration or pneumonia, rather than just an improvement of oxygenation caused by iNO.
A major concern of our study design is possible toxicity from nitric oxide. The basic premise of our design was that reversal of pulmonary vasoconstriction by iNO, to attain optimal vasodilation (maximal oxygenation), would expedite weaning of ventilatory support. The concentration of iNO was kept constant while ventilation support was weaned until just prior to extubation. As can be seen in Figure 3 , this strategy was successful with iNOtreated patients consistently requiring less ventilation support than control patients. The mean duration of iNO use in our study was 96±9 hours, which is similar to that reported by Kinsella et al.
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(9513 h) and Finer et al. 12 (91±67 hours SD). It is likely that iNO toxicity in our study is similar to that of other studies since methemoglobin levels did not exceed 5% (mean 1.45%, range 0-3.5%) in our study, and the incidence of chronic lung disease in our study is comparable to that reported in the literature. 4, 9, 12 The incidence of hemorrhage from any site was not increased with iNO use in our study.
Our results are limited by the fact that the study was not blinded. All personnel involved in care of the infant were aware of the group assignment. It is unlikely that this would have affected actual measurements of p a O 2 and improvements in oxygenation but could possibly affect ventilator management strategies. Guidelines for weaning ventilator support were the same for both groups. Weaning of ventilation parameters was not a predefined secondary outcome variable and so it is unlikely that the personnel were focussed on weaning as a study goal.
In summary, we have shown, in patients with moderate pulmonary hypertension of the newborn, that iNO is effective in preventing progression to severe PPHN. In addition, when combined with a strategy that maximizes arterial p a O 2 , iNO use allows more rapid weaning of mechanical ventilation support and inspired oxygen concentrations. 
